Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Impact of adipose-derived mesenchymal stem cells and their secretome on osteoarthritis in a rat model.

Palombella S., Lopa S., Recordati C., Canesi S., Moretti M., Lovati AB.

Prospective Study on Osteoarthritis, published in BMC Musculoskelet Disord (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
BMC Musculoskelet Disord (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40259333
PMCID
PMC12010554
DOI
10.1186/s12891-025-08642-8

Abstract (original English)

Background Osteoarthritis is a common degenerative joint disease marked by cartilage degeneration and inflammation. This study investigates the therapeutic potential of adipose-derived stromal cells (ASCs) and their secretome in a rat model of osteoarthritis. Methods ASCs were extracted from human adipose tissue, cultured, and primed with human platelet lysate. The secretome was collected after 48 h of serum-free culture. Osteoarthritis was induced in rats using monosodium iodoacetate, and after 14 days, they were treated with saline solution, ASCs, or secretome. Over five weeks, body weight and histopathological changes were monitored. Results No clinical complications arose post-treatment, and all rats gained weight similarly. ASC treatment increased histopathological changes associated with osteoarthritis, including severe cartilage necrosis and bone remodeling. Conversely, the secretome treatment resulted in mild to moderate cartilage degeneration, similar to that observed in the control group. These findings suggest that ASCs may contribute to disease progression in this model, while the secretome did not show significant effects on cartilage histology compared to the control group. Further studies are needed to determine whether optimizing the secretome composition or dosing could enhance its therapeutic potential. Conclusions This study highlights the complexity of ASC i

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AnimalsMesenchymal Stem CellsSecretomeOsteoarthritisRatsMesenchymal Stem Cell TransplantationAdipose TissueHumansMaleDisease Models, Animal

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research